SCHEMBL8122210

SCHEMBL8122210

COc1ccc(OCC[C@@H]2CN(C(=O)OCc3ccccc3)CCN2C(=O)OC(C)(C)C)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.51
▸ PDE4B Q07343 3/20 0.46
▸ BCL9 O00512 2/20 0.45
▸ CTNNB1 P35222 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ TP53 P04637 1/20 0.43
▸ PTGDR2 Q9Y5Y4 2/20 0.42
▸ MMP1 P03956 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ MMP9 P14780 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ TLR9 Q9NR96 3/20 0.41
▸ PDK1 Q15118 1/20 0.41
▸ PDK2 Q15119 1/20 0.41
▸ PDK3 Q15120 1/20 0.41
▸ PDK4 Q16654 1/20 0.41
▸ TLR7 Q9NYK1 2/20 0.41
▸ OPRK1 P41145 1/20 0.40
▸ YAP1 P46937 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8113703 0.94 PARP1 (0.52) PARP1PDE4BBCL9CTNNB1ALDH1A1
SCHEMBL13705543 0.89 PARP1 (0.53) PARP1BCL9CTNNB1MMP1MMP3
SCHEMBL4860080 0.89 PARP1 (0.58) PARP1BCL9CTNNB1PDK1PDK2
SCHEMBL13340759 0.89 PARP1 (0.58) PARP1BCL9CTNNB1PDK1PDK2
SCHEMBL4860072 0.89 PARP1 (0.58) PARP1BCL9CTNNB1PDK1PDK2
SCHEMBL13705325 0.89 PARP1 (0.52) PARP1PDE4BBCL9CTNNB1ALDH1A1
SCHEMBL13705539 0.88 PARP1 (0.55) PARP1BCL9CTNNB1PTGDR2PDK1
SCHEMBL13705324 0.88 PARP1 (0.49) PARP1PDE4BBCL9CTNNB1ALDH1A1
SCHEMBL8109520 0.88 PARP1 (0.49) PARP1PDE4BBCL9CTNNB1ALDH1A1
SCHEMBL8123342 0.87 PARP1 (0.52) PARP1BCL9CTNNB1ALDH1A1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 — — US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 — — US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT PARP1 3523/4885PDE4B 242/4885BCL9 4342/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT PARP1 3523/4885PDE4B 242/4885BCL9 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback